Role of MMP-1 (-519A/G, -1607 1G/2G), MMP-3 (Lys45Glu), MMP-7 (-181A/G), and MMP-12 (-82A/G) Variants and Plasma MMP Levels on Obesity-Related Phenotypes and Microvascular Reactivity in a Tunisian Population
Table 4
Genotype distribution and allele frequencies of MMP-1 (-519A/G; -1607 1G/2G), MMP-3 Lys45Glu (A/G), MMP-7 (-181A/G), and MMP-12 (-82A/G) polymorphisms among nonobese, nonmorbidly obese, and morbidly obese.
SNP
Genotypes and alleles
Nonobese£ (, %)
Nonmorbidly obese£ (, %)
Adjusted OR (95% CI)
a
Morbidly obese£ (, %)
Adjusted OR (95% CI)
b
MMP-1 (-519A/G)
(rs1144393)
AA n (%)
106 (53)
41 (38.4)
1
24 (42.1)
1
AG n (%)
83 (41.5)
59 (55.1)
1.5 (0.9–2.5)
0.12
26 (45.6)
1.38 (0.72–2.64)
0.33
GG n (%)
11 (5.5)
7 (6.5)
1.6 (0.56–4.6)
0.38
7 (12.3)
3.01 (1.08–4.04)
0.05
AG+GG n (%)
94 (47)
66 (61.6)
0.66 (0.4–1.1)
0.1
33 (57.9)
1.56 (0.84–2.9)
0.15
A n (%)
295 (73.75)
141 (65.89)
1
74 (64.91)
1
G n (%)
105 (26.25)
73 (34.11)
1.45 (1.01-2.08)
0.06
40 (35.09)
1.51 (0.97–2.36)
0.06
MMP-1 (-1607 1G/2G)
(rs1799750)
1G1G n (%)
24 (12)
16 (15)
1
6 (10.5)
1
1G2G n (%)
75 (37.7)
41 (38.3)
0.85 (0.39–1.86)
0.68
21 (36.8)
1.18 (0.41–3.41)
0.75
2G2G n (%)
100 (50.3)
50 (46.7)
0.8 (0.37–1.72)
0.57
30 (52.7)
1.26 (0.45–3.52)
0.65
1G2G+2G2G n (%)
175 (88)
91 (85)
0.82 (0.40–1.7)
0.6
51 (89.5)
1.23 (0.46–3.3)
0.67
1G n (%)
123 (30.9)
73 (34.11)
1
33 (28.95)
1
2G n (%)
275 (69.1)
141 (65.89)
0.86 (0.60–1.23)
0.41
81 (71.05)
1.1 (0.70–1.73)
0.68
MMP-3 Lys45Glu (A/G)
(rs679620)
AA n (%)
69 (34.2)
25 (23.5)
1
8 (13.8)
1
AG n (%)
100 (49.5)
59 (55.7)
1.51 (0.84–2.73)
0.16
34 (58.6)
2.83 (1.20–6.68)
0.01
GG n (%)
33 (16.3)
22 (20.8)
1.8 (0.85–3.78)
0.12
16 (27.6)
4.93 (1.84–13.32)
0.002
AG+GG n (%)
133 (65.8)
81 (76.5)
1.58 (0.90–2.77)
0.1
50 (86.2)
3.31 (1.45–7.56)
0.005
A n (%)
238 (58.91)
109 (51.42)
1
50 (43.1)
1
G n (%)
166 (41.09)
103 (48.58)
1.35 (0.96–1.9)
0.07
66 (56.9)
1.9 (1.24–2.87)
0.002
MMP-7 (-181A/G)
(rs11568818)
AA n (%)
53 (26.2)
32 (30.2)
1
5 (8.5)
1
AG n (%)
103 (51)
56 (52.8)
0.99 (0.60–1.78)
0.99
36 (61)
3.68 (1.40–6.71)
0.01
GG n (%)
46 (22.8)
18 (17)
0.65 (0.31–1.36)
0.65
18 (30.5)
3.4 (1.19–6.68)
0.02
AG+GG n (%)
149 (73.8)
74 (69.8)
0.88 (0.51–1.54)
0.67
54 (91.5)
3.58 (1.40–9.14)
0.008
A n (%)
209 (51.73)
120 (56.6)
1
46 (38.98)
1
G n (%)
195 (48.27)
92 (43.4)
0.82 (0.58–1.14)
0.25
72 (61.02)
1.67 (1.10–2.54)
0.02
MMP-12 (-82A/G)
(rs2276109)
AA n (%)
178 (88.6)
82 (76.6)
1
43 (74.1)
1
AG n (%)
23 (11.4)
25 (23.4)
1.58 (0.90–2.77)
0.01
14 (24.1)
2.2 (1.21–3.97)
0.01
GG n (%)
0
0
0.99
1 (1.8)
0.99
AG+GG n (%)
23 (11.4)
25 (23.4)
1.58 (0.90–2.77)
0.01
15 (25.9)
2.6 (1.21–5.56)
0.01
A n (%)
379 (94.28)
189 (88.32)
1
100 (86.21)
1
G n (%)
23 (5.72)
25 (11.68)
2.17 (1.20–3.94)
0.008
16 (13.79)
2.63 (1.34–5.17)
0.003
The chi-square (χ2) test was used for the determination of genotype distribution between nonobese and obese class I-II and between nonobese and obese class III. Adjustments for age and sex were performed by logistic regression analysis. a (nonobese versus obese class I-II) and b (nonobese versus obese class III (morbid)). CI: confidence interval; OR: odds ratio. value remained significant after the Bonferroni correction. £The sum does not add up to the total because of a few missing genotypes.
